---
title: "PhenoAge DNA Methylation Acceleration Predicts Adolescent Depressive Symptoms: Longitudinal and MR"
id: "medrxiv-13-dna-methylation-age-acceleration-depression-and-anxiety-evidence-from-a"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-13-dna-methylation-age-acceleration-depression-and-anxiety-evidence-from-a"
content_type: "clinical_feed_article"
specialty: "Pediatrics"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.15.26362972v1?rss=1"
published_at: "2026-09-16T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# PhenoAge DNA Methylation Acceleration Predicts Adolescent Depressive Symptoms: Longitudinal and MR
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-13-dna-methylation-age-acceleration-depression-and-anxiety-evidence-from-a
- **Specialty:** [Pediatrics](https://medichelpline.com/clinical-feed/pediatrics.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.15.26362972v1?rss=1)
- **Published At:** 2026-09-16T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This study examined whether DNA methylation (DNAm) age acceleration in early adolescence predicts later depressive and anxiety symptoms, using both longitudinal analysis and Mendelian randomisation (MR). - A subsample of 261 adolescents from the SCAMP cohort provided saliva at ages 11–12 years for DNAm profiling; age acceleration was calculated using the **Horvath**, **PhenoAge**, and **PedBE** clocks. - Depressive symptoms were assessed at ages 13–15 years with the Patient Health Questionnaire; anxiety symptoms were measured with the Generalised Anxiety Disorder scale. - Longitudinal logistic regression showed that **PhenoAge** acceleration at 11–12 years was associated with higher depressive symptom severity (OR 1.04, 95% CI 1.01–1.08) and clinically significant depressive symptoms (OR 1.05, 95% CI 1.01–1.10). - No associations were observed between any of the three DNAm clocks and anxiety outcomes in the adolescent follow-up. - Two-sample MR analyses indicated a potential causal link between **PhenoAge** acceleration and depression (IVW OR 1.01, 95% CI 1.00–1.02), consistent with the observational findings. - The pattern of results supports **PhenoAge** acceleration as a possible early biomarker for subsequent depressive symptoms in adolescents, while evidence for anxiety was null. - Data access and GWAS summary statistics sources are reported; study approvals and ethical oversight were obtained via the North-West Haydock Research Ethics Committee (14/NW/0347). - The authors declared no competing interests and acknowledged funders including the Medical Research Council and NIHR.
## Clinical Analysis & Structured Key Points
DNA methylation age acceleration, depression and anxiety: evidence from a longitudinal adolescent cohort study (SCAMP) and Mendelian Randomisation | medRxiv Skip to main content DNA methylation age acceleration, depression and anxiety: evidence from a longitudinal adolescent cohort study (SCAMP) and Mendelian Randomisation View ORCID Profile Chen Shen , View ORCID Profile Oliver Robinson , View ORCID Profile Paolo Vineis , View ORCID Profile Dougal S Hargreaves , View ORCID Profile Dasha Nicholls , View ORCID Profile Abbas Dehghan , View ORCID Profile Mireille B Toledano doi: https://doi.org/10.64898/2026.09.15.26362972 Chen Shen Imperial College London Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Chen Shen For correspondence: chen.shen{at}imperial.ac.uk Oliver Robinson Imperial College London Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Oliver Robinson Paolo Vineis Imperial College London Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Paolo Vineis Dougal S Hargreaves Imperial College London Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Dougal S Hargreaves Dasha Nicholls Imperial College London Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Dasha Nicholls Abbas Dehghan Imperial College London Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Abbas Dehghan Mireille B Toledano Imperial College London Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Mireille B Toledano Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background DNA methylation (DNAm) based age acceleration is an indicator of biological ageing. However, it is unclear how age acceleration is linked to mental health in adolescents. We examined the longitudinal associations between DNAm age acceleration and depression and anxiety in adolescents. We also triangulated the evidence using Mendelian Randomisation (MR). Methods We analysed a subsample of adolescents (n=261) from a London-based adolescent cohort study. DNAm profile was generated from saliva samples collected at ages 11-12 years. DNAm age acceleration measures were derived from Horvath, PhenoAge, and PedBE clocks. Depressive and anxiety symptoms were measured at ages 13-15 years, using the Patient Health Questionnaire and Generalised Anxiety Disorder scale, respectively. The associations between DNAm age acceleration and depressive and anxiety symptoms were assessed using logistic regression. We also conducted a two-sample MR to investigate the potential causal relationship between Horvath and PhenoAge acceleration and depression and anxiety. Results We found that PhenoAge age acceleration was associated with higher severity levels of depressive symptoms (OR=1.04, 95% CI 1.01, 1.08) and clinically significant depressive symptoms (OR=1.05, 95% CI 1.01, 1.10). None of these three clocks was associated with anxiety outcomes. MR suggested a potential causal relationship between PhenoAge age acceleration and depression (Inverse variance weighted OR = 1.01, 95% CI 1.00, 1.02). Conclusions PhenoAge acceleration at ages 11-12 years was associated with depressive symptoms at ages 13-15 years. The association patterns are consistent between longitudinal and MR analyses. PhenoAge acceleration may represent a potential early biomarker for subsequent depressive symptoms in adolescents. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The SCAMP protocol and subsequent amendments were approved by the North-West Haydock Research Ethics Committee (14/NW/0347). Headteachers of schools consented to participate in SCAMP. Participants were provided in advance with written information about the study and were given the opportunity to opt out of the research at any time. The study was conducted in accordance with the Declaration of Helsinki. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability According to the participant consent, access to individual-level SCAMP data needs to be approved by the SCAMP Data Access Committee (https://scampstudy.org/get-involved/opportunities-for-researchers/). Application should be made to scamp{at}imperial.ac.uk. The data dictionary is available on request to the corresponding author. The GWAS summary statistics used in this study are publicly available at the following repositories: https://figshare.com/articles/dataset/GWAS_summary_statistics_for_major_depression_PGC_MDD2025_/27061255; https://figshare.com/articles/dataset/anx2026/31389910; https://datashare.ed.ac.uk/items/57cb0570-984b-41da-9fb5-b6831b327487. https://scampstudy.org/get-involved/opportunities-for-researchers Funder Information Declared Medical Research Council, https://ror.org/03x94j517 , MR/V004190/1 , MR/S019669/1 National Institute for Health and Care Research , 091/0212 , NIHR207424 , NIHR200922 NIHR Imperial Biomedical Research Centre, https://ror.org/01kmhx639 , PSR917 Rosetrees Trust , PGL23/100104 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted September 16, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following DNA methylation age acceleration, depression and anxiety: evidence from a longitudinal adolescent cohort study (SCAMP) and Mendelian Randomisation Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share DNA methylation age acceleration, depression and anxiety: evidence from a longitudinal adolescent cohort study (SCAMP) and Mendelian Randomisation Chen Shen , Oliver Robinson , Paolo Vineis , Dougal S Hargreaves , Dasha Nicholls , Abbas Dehghan , Mireille B Toledano medRxiv 2026.09.15.26362972; doi: https://doi.org/10.64898/2026.09.15.26362972 Share This Article: Copy Citation Tools DNA methylation age acceleration, depression and anxiety: evidence from a longitudinal adolescent cohort study (SCAMP) and Mendelian Randomisation Chen Shen , Oliver Robinson , Paolo Vineis , Dougal S Hargreaves , Dasha Nicholls , Abbas Dehghan , Mireille B Toledano medRxiv 2026.09.15.26362972; doi: https://doi.org/10.64898/2026.09.15.26362972 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (617) Allergy and Immunology (902) Anesthesia (333) Cardiovascular Medicine (4819) Dentistry and Oral Medicine (479) Dermatology (415) Emergency Medicine (650) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1629) Epidemiology (15953) Forensic Medicine (33) Gastroenterology (1203) Genetic and Genomic Medicine (7050) Geriatric Medicine (733) Health Economics (1065) Health Informatics (5051) Health Policy (1435) Health Systems and Quality Improvement (1768) Hematology (585) HIV/AIDS (1344) Infectious Diseases (except HIV/AIDS) (16295) Intensive Care and Critical Care Medicine (1173) Medical Education (668) Medical Ethics (155) Nephrology (724) Neurology (7276) Nursing (368) Nutrition (1082) Obstetrics and Gynecology (1241) Occupational and Environmental Health (1005) Oncology (3610) Ophthalmology (1053) Orthopedics (398) Otolaryngology (457) Pain Medicine (470) Palliative Medicine (139) Pathology (709) Pediatrics (1799) Pharmacology and Therapeutics (737) Primary Care Research (767) Psychiatry and Clinical Psychology (5902) Public and Global Health (9761) Radiology and Imaging (2425) Rehabilitation Medicine and Physical Therapy (1453) Respiratory Medicine (1249) Rheumatology (641) Sexual and Reproductive Health (771) Sports Medicine (578) Surgery (780) Toxicology (107) Transplantation (305) Urology (291)
## Related Clinical Research

- [Age-Dependent Differences in Disease Risk for People with Down Syndrome](https://medichelpline.com/clinical-feed/medrxiv-14-effects-of-age-on-the-association-between-down-syndrome-and-common-disease.md)
- [Understanding Parasitic Identification in Delusional Parasitosis](https://medichelpline.com/clinical-feed/plos-one-21-bridging-perception-and-reality-parasitic-identification-in-delusional.md)
- [More REM (dream) sleep linked to lower risk of 83 diseases—UK Biobank study](https://medichelpline.com/clinical-feed/medical-news-today-0-more-dream-sleep-linked-to-lower-risk-of-83-diseases-including-diabetes.md)
- [Rising Demand for Plastic Surgery Among Young Men Fueled by Influencers and Looksmaxxing](https://medichelpline.com/clinical-feed/stat-news-1-opinion-more-young-men-are-coming-to-me-for-plastic-surgery-the-way-i-think.md)
- [Synbiotic Supplementation and Psychobiotic Diet for Depression and Anxiety in Gestational Diabetes](https://medichelpline.com/clinical-feed/bmj-open-6-effect-of-synbiotic-supplementation-and-psychobiotic-diet-on-prenatal-and.md)

## Navigation
- [← Back to Pediatrics Feed](https://medichelpline.com/clinical-feed/pediatrics.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.